Search Results

November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID --(BUSINESS WIRE)--Nov. 15, 2021-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers Biopharma, a division of Twist Bioscience, that neutralizes all known variants of concern of the SARS-CoV addition, Revelar will have the ability to leverage the antibody discovery and optimization platform of Twist Biopharma to license additional antibodies for up to five targets over the next four years."

December 2022 Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR Targets "Collaboration aims to combine Twist’s proprietary TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering

Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates.

Aaron Sato from Twist Biopharma , a vertical within Twist Bioscience . During our time together, Aaron and I discussed how using Twist Bioscience’s proprietary technology to identifying novel functional antibodies targeting GPCRs by incorporating these natural binding partners into Twist We’d like to extend a special thanks to Twist Biopharma for sponsoring this episode of the Dr. Aaron Sato on the web LinkedIn Twitter Google Scholar Twist Bioscience Twist Biopharma Dr.

These roles included management of PerkinElmer’s BioPharma R&D program and Chair of the company’s Scientific

Murat Tunaboylu on the web Antiverse DSV Future of Drug Discovery Podcast Twist Bioscience LinkedIn Twitter